Zydus Lifesciences buyback: ₹1,100-cr plan, May 29 record date

Shares jump as buyback and Q4 beat drive sentiment

Shares of Zydus Lifesciences Ltd. gained over 5% on Tuesday, May 19, after the company approved a share buyback and reported a stronger-than-expected March quarter performance. The company said profit, revenue and margins for the March quarter beat Street estimates. The buyback announcement came alongside the January to March quarter results for fiscal 2025-26 (Q4FY26). The move placed Zydus Lifesciences among a set of large pharmaceutical companies using capital returns to support shareholder value. The immediate stock reaction reflected the combined effect of earnings surprise and a buyback price set above the prevailing market level.

What the board approved on May 19, 2026

At its meeting held on 19 May 2026, the board approved a proposal to buy back up to 95,65,217 fully paid-up equity shares. The buyback price is set at ₹1,150 per equity share, payable in cash. The total buyback size is capped at ₹1,100 crore. The company will execute the repurchase through the tender offer route. This structure implies eligible shareholders can tender their shares during the offer window, subject to acceptance levels and category-wise entitlements set out in the offer documents.

Buyback size, share count, and equity impact

The approved repurchase is for up to 95.65 lakh shares, which the company said represents 0.95% of its equity stake. In other words, the announced buyback is relatively small as a percentage of total equity but meaningful as an absolute cash outlay. The price point of ₹1,150 per share sets a clear reference for investors assessing participation. Tender offer buybacks typically see different acceptance ratios for retail and non-retail categories, but Zydus Lifesciences has not provided those details in the information shared here.

Tender offer route and promoter participation

Zydus Lifesciences said the buyback will be conducted via the tender offer route. Promoters will also participate in the buyback. Promoter participation can influence the final distribution of acceptances between categories, depending on how much is tendered. It also signals that the offer is open to all eligible shareholders, including the promoter group, in line with the company’s stated plan.

Record date set: May 29, 2026

The company fixed May 29, 2026 as the record date for determining shareholder eligibility. This means shareholders holding Zydus Lifesciences shares as of the record date, as per applicable settlement rules, will be considered eligible to tender shares in the buyback. The record date is a key operational marker for investors, brokers, and registrars as it determines the eligible shareholder base for the offer.

Buyback price at a 16% premium to prior close

The buyback price is at a premium of 16% compared with the company’s closing price on Monday. A premium is typical in tender offers, as it is designed to encourage shareholders to tender shares. For investors, the premium is one of the main inputs while evaluating whether to participate, alongside expected acceptance ratios and the opportunity cost of selling shares in the market.

Q4FY26 results: beats on profit, revenue, and margins

Along with the buyback, Zydus Lifesciences reported its January to March quarter results for fiscal 2025-26. The company’s profit, revenue, and margins beat Street estimates, according to the information provided. While specific figures were not shared here, the statement indicates performance exceeded analyst expectations on multiple operating metrics. The combination of stronger operating performance and capital return actions often draws incremental investor attention in the short term.

Context: Zydus Lifesciences buyback executed in 2024

Zydus Lifesciences previously concluded a share buyback programme in 2024. In that buyback, the company repurchased 59,70,149 equity shares at ₹1,005 per share, totalling ₹599.99 crore. The offer was oversubscribed by 8.66 times, with 45,308 valid bids received for 5,16,87,188 shares. The tendering period ran from February 29 to March 6, 2024, with settlement on March 14. The record date for eligibility in that programme was February 23, 2024.

Key facts at a glance

Why the announcement matters for investors

For investors, the immediate relevance is twofold: a tender offer at ₹1,150 per share and a record date of May 29, 2026 that determines eligibility. The stated 16% premium to the prior close provides a benchmark for comparing the offer price with the prevailing market price. The announcement also arrived alongside a quarter where profit, revenue and margins beat Street estimates, which can shape near-term market perception. Separately, the company’s 2024 buyback experience, including significant oversubscription, shows that tender offers can attract heavy participation depending on market conditions and expectations.

Conclusion

Zydus Lifesciences’ board-approved buyback of up to ₹1,100 crore at ₹1,150 per share, with May 29, 2026 as the record date, helped push the stock up over 5% on May 19. The company also indicated its March quarter performance beat Street estimates on profit, revenue and margins. The next operational milestone for shareholders is the record date, after which detailed timelines and participation mechanics typically follow through formal filings and offer documents.